Periurethral Estrogen Application for Urinary Tract Infections, Recurrent

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
University of Pittsburgh Medical Center- Magee Womens Hospital, Pittsburgh, PA
Urinary Tract Infections, Recurrent+4 More
Periurethral application of estradiol cream - Drug
Eligibility
18+
Female
What conditions do you have?
Select

Study Summary

Due to rising antibiotic resistance, there has been a focus on non-antibiotic prophylactic measures for postmenopausal patients with recurrent urinary tract infections (rUTI), one of which is the safe and efficacious option of vaginal estrogen therapy. Standard application of vaginal estrogen cream entails intravaginal application of the cream twice a week, but some providers counsel patients with rUTI to apply a small, pea-sized amount to the periurethral area. This ideally reduces the amount of vaginal estrogen used while attaining a similar effect. However, to date, there is no data to prove that the periurethral technique of application is similar or non-inferior to intravaginal application in preventing UTI.

Eligible Conditions

  • Urinary Tract Infections, Recurrent

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Urinary Tract Infections, Recurrent

Study Objectives

1 Primary · 10 Secondary · Reporting Duration: 6 months

6 months
Amount of estrogen cream used
Participant experience with use of estrogen cream
Time to urinary tract infection
Baseline, 6 months
Change from baseline in Vaginal and urinary E. coli levels at 6 months
Change from baseline in Vaginal and urinary Lactobacillus levels at 6 months
Change from baseline in periurethral maturation index at 6 months
Change from baseline in sexual function at 6 months
Change from baseline in urinary symptoms at 6 months
Change from baseline in vaginal maturation index at 6 months
Change from baseline in vaginal pH at 6 months
Change from baseline in vaginal symptoms at 6 months

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Other trials for Urinary Tract Infections, Recurrent

Trial Design

2 Treatment Groups

Intravaginal Estrogen Application
1 of 2
Periurethral Estrogen Application
1 of 2
Active Control
Experimental Treatment

102 Total Participants · 2 Treatment Groups

Primary Treatment: Periurethral Estrogen Application · No Placebo Group · Phase 2

Periurethral Estrogen Application
Drug
Experimental Group · 1 Intervention: Periurethral application of estradiol cream · Intervention Types: Drug
Intravaginal Estrogen Application
Drug
ActiveComparator Group · 1 Intervention: Intravaginal application of estradiol cream · Intervention Types: Drug

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 6 months
Closest Location: University of Pittsburgh Medical Center- Magee Womens Hospital · Pittsburgh, PA
Photo of Pittsburgh  1Photo of Pittsburgh  2Photo of Pittsburgh  3
N/AFirst Recorded Clinical Trial
1 TrialsResearching Urinary Tract Infections, Recurrent
0 CompletedClinical Trials

Eligibility Criteria

Age 18+ · Female Participants · 4 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have 2 or more UTIs in 6 months or 3 or more UTIs in 1 year.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.